Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD
- Conditions
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT05722912
The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT05696392
- Locations
- 🇺🇸
First Oc Dermatology, Fountain Valley, California, United States
🇺🇸Ark Clinical Research, Long Beach, California, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
- Conditions
- Interventions
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 69
- Registration Number
- NCT05635838
- Locations
- 🇺🇸
Revival Research Institute, Llc Troy, Troy, Michigan, United States
🇺🇸International Clinical Research Tennessee Llc, Murfreesboro, Tennessee, United States
🇺🇸Dermatology Associates of Plymouth Meeting, Plymouth Meeting, Pennsylvania, United States
A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT05624710
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Texas Liver Institute Tli the Liver Institute of South Texas List Downtown Office, San Antonio, Texas, United States
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 43
- Registration Number
- NCT05624723
- Locations
- 🇩🇪
Apex Gmbh, Munich, Germany
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
- Conditions
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 619
- Registration Number
- NCT05620836
- Locations
- 🇺🇸
Investigative Site US240, Scottsdale, Arizona, United States
🇺🇸Investigative Site US237, Scottsdale, Arizona, United States
🇺🇸Investigative Site US214, Arkansas, Arkansas, United States
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
- Conditions
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 609
- Registration Number
- NCT05620823
- Locations
- 🇺🇸
Investigative Site US303, Phoenix, Arizona, United States
🇺🇸Investigative Site US335, Arkansas, Arkansas, United States
🇺🇸Investigative Site US315, Laguna Niguel, California, United States
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus
- Conditions
- Interventions
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 64
- Registration Number
- NCT05593432
- Locations
- 🇺🇸
Northshore Medical Group Dermatology Skokie, Skokie, Illinois, United States
🇺🇸Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸Dermassociates, Rockville, Maryland, United States
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 61
- Registration Number
- NCT05593445
- Locations
- 🇺🇸
New Age Medical Research Corporation, Miami, Florida, United States
🇺🇸UC Irvine, Irvine, California, United States
🇺🇸Circuit Clinical, West Seneca, New York, United States
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 120
- Registration Number
- NCT05577182
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸University of Texas Md Anderson Cancer Center, Houston, Texas, United States
🇧🇪Cliniques Universitaires Ucl Saint-Luc, Bruxelles, Belgium